Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B), while iShares 10 20 Year Treasury Bond ETF trades at $94.08 (market cap $11.48B). The key difference: iShares 10 20 Year Treasury Bond ETF is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and iShares 10 20 Year Treasury Bond ETF for 62 Days on average.
| SYRE | TLH | |
|---|---|---|
Market Cap | $7.35B | $11.48B |
Volume | 1,624,631 | 3,119,674 |
Sector | Health | Fixed Income |
52-Week High | $108.92 | $105.36 |
52-Week Low | $22.18 | $91.34 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $6.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
TLH, the iShares 10-20 Year Treasury Bond ETF, trades at $92.56 with a slight 0.34% daily gain amid a challenging bond market environment. Technical indicators signal a bearish trend with selling pressure outweighing buying signals. Recent trading volume spikes indicate heightened investor interest as Treasury yields reach multi-decade highs, creating volatility for long-duration bond ETFs.
The outlook remains cautious as rising interest rates pressure bond prices, though the ETF provides exposure to US Treasury securities. Key risks include continued Fed tightening and inflation concerns, while potential stabilization in yields could offer support. Institutional activity shows mixed positioning with some funds reducing exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
